Biopharmaceutical major Biocon has crossed the Rs 3000 crore revenue milestone.

The company's CMD Kiran Mazumdar Shaw detailed its second quarter and first half performance during a press conference. “I am pleased to report that at Q2 level the total revenues delivered were Rs 1,611 crore which is up 17 percent year on year. EBITDA rose 12 percent to Rs 441 crore and net profit after excluding exceptional items rose 12 percent and this resulted in Rs 189 crore at net profit level," she said.

Translating all these numbers at an H1 level, the group has crossed

Rs 3000-crore revenue milestone, posting Rs 3101 crore, which is a 21 percent year-on-year increase, said Shaw, adding that EBITDA margins at H1 level were at 29 percent, which is up from previous year’s 27 percent.

“Core EBITDA margins which exclude R&D expenses, forex gains, licensing income and Syngene were maintained at 33 percent both in terms of quarter as well as half year numbers,” she said.

First Published:Oct 24, 2019 12:19 PM IST